Low Dose Naltrexone Versus Gabapentinoid Standard of Care Treatment for Fibromyalgia: A Retrospective Cohort Study

Saturday, November 15, 2025

8:00 AM - 8:08 AM CT

Location: 301 - 302

Introduction:

Fibromyalgia inflicts debilitating pain and fatigue. Standard of care therapies (e.g. gabapentinoids, SNRIs) are limited in their ability to relieve symptoms and have side effects.^1,2

Low-dose naltrexone (LDN), at a dose of 6 mg or less, has been proposed as a fibromyalgia treatment. LDN works by expressing an anti-inflammatory microglia phenotype.³ Studies have demonstrated significant pain improvements in LDN-treated fibromyalgia patients.^4,5 While LDN appears to have benefit, there is little literature comparing it to gabapentinoids.

Presenting Author(s)

NC

Nicole Christy, n/a

Student
University of Virginia, United States
MK

Morena Koorie, B.S.

Student
Drexel University, United States

Co-Author(s)

YA

Yamilay Andre, B.S.

Student
The City University of New York, United States

Presenting Author(s)

WK

William Kindschuh, M.D., Ph.D.

Resident
Columbia University, United States

Submitting Author(s)

AA

Andrew Aboujaoude, M.D., Capt.

Resident
Columbia University
New York, New York, United States

Co-Author(s)

LC

Luis Chabla-Penafiel, M.D.

Assistant Professor
Columbia University, United States